KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Deferred Revenue (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Current Deferred Revenue for 13 consecutive years, with $6.8 million as the latest value for Q1 2025.

  • Quarterly Current Deferred Revenue fell 41.47% to $6.8 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Mar 2025, down 41.47% year-over-year, with the annual reading at $7.6 million for FY2024, 35.79% down from the prior year.
  • Current Deferred Revenue hit $6.8 million in Q1 2025 for Arbutus Biopharma, down from $7.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $23.3 million in Q1 2022 to a low of $6.8 million in Q1 2025.
  • Historically, Current Deferred Revenue has averaged $13.4 million across 4 years, with a median of $12.1 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: decreased 9.7% in 2023 and later crashed 41.47% in 2025.
  • Year by year, Current Deferred Revenue stood at $16.5 million in 2022, then decreased by 28.35% to $11.8 million in 2023, then tumbled by 35.79% to $7.6 million in 2024, then dropped by 10.73% to $6.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ABUS at $6.8 million in Q1 2025, $7.6 million in Q4 2024, and $10.9 million in Q3 2024.